Abstract The tumor microenvironment (TME), which is composed of stromal cells such as endothelial cells, fibroblasts, and immune cells, provides a supportive niche promoting the growth and invasion of tumors. The TME also raises an immunosuppressive barrier to effective antitumor immune responses and is therefore emerging as a target for cancer immunotherapies. Mast cells (MCs) accumulate in the TME at early stages, and their presence in the TME is associated with poor prognosis in many aggressive human cancers. Some well-established roles of MCs in cancer are promoting angiogenesis and tumor invasion into surrounding tissues. Several mouse models of inducible and spontaneous cancer show that MCs are among the first immune cells to accumulate within and shape the TME. Although MCs and other suppressive myeloid cells are associated with poor prognosis in human cancers, high densities of intratumoral T effector (T eff ) cells are associated with a favorable prognosis. The latter finding has stimulated interest in developing therapies to increase intratumoral T cell density. However, cellular and molecular mechanisms promoting high densities of intratumoral T eff cells within the TME are poorly understood. New evidence suggests that MCs are essential for shaping the immune-suppressive TME and impairing both antitumor T eff cell responses and intratumoral T cell accumulation. These roles for MCs warrant further elucidation in order to improve antitumor immunity. Here, we will summarize clinical studies of the prognostic significance of MCs within the TME in human cancers, as well as studies in mouse models of cancer that reveal how MCs are recruited to the TME and how MCs facilitate tumor growth. Also, we will summarize our recent studies indicating that MCs impair generation of protective antitumor T cell responses and accumulation of intratumoral T eff cells. We will also highlight some approaches to target MCs in the TME in order to unleash antitumor cytotoxicity.
Introduction
MCs are among the first immune cells to infiltrate the TME, contributing to tumor progression in multiple aggressive types of human cancer. Their role in tumor progression has been largely attributed to promoting tumor angiogenesis and invasion. However, less is known about how MCs influence adaptive antitumor T cell responses and immune suppression in the TME. Although host immunity can sometimes control cancer, tumors that have become clinically evident have already evaded antitumor immunity, at least in part, by establishing an immunosuppressive TME [1] . The early accumulation of MCs in the TME reflects their role as tissueresident sentinel cells poised for rapid responses to pathogens and immunogenic antigens [2] . MCs are capable of modulating both innate and adaptive immune responses [3] . Furthermore, MCs have emerged as critical intermediaries in the regulation of peripheral tolerance [4] . Their presence in many precancerous lesions and human tumors is associated with a poor prognosis. This suggests that MCs may contribute to an immunosuppressive TME and thereby impede the development of protective antitumor immunity. Here, we will review studies of MCs and their prognostic significance in human cancers. We will discuss mechanisms of how MCs influence immune responses to tumors from experimental models of cancer. We will also discuss recent studies of MCs and their regulation of T eff cells within immune privileged sites, including the TME.
MCs are correlated with poor prognosis in many human cancers
A high density of MCs in many human cancers is significantly correlated with poor prognosis (decreased survival and increased tumor recurrence). High densities of tumorassociated MCs predict poor prognoses in aggressive skin cancers such as Merkel cell carcinoma and malignant melanoma [5] [6] [7] . Similarly, MCs accumulate in nearly all Hodgkin's lymphomas and those patients with highest MC infiltration have significantly worse relapse-free survival rates [8] . MCs accumulate in premalignant lesions of colorectal cancer, that is, adenomatous polyps, suggesting their involvement in these tumors at the earliest stages [9] . MCs also contribute to angiogenesis of colorectal tumors as reflected by increased microvascular density (MVD) in tumor tissues. Thus, high MVD and high MC counts positively correlated with each other and high levels of both histological features were significantly correlated with poor prognosis, that is, a shorter duration of disease-free survival [10] . Supporting this, the invasive fronts of colorectal tumors contain ''hot spots'' of angiogenesis, which were identified as regions of high MVD with respect to other regions of the tumor. Increased MVD and MC density in hot spots were associated with worse overall survival in patients with colorectal cancer [11] .
Similarly, high densities of MCs infiltrating human pancreatic cancers are correlated with poor prognosis. MCs accumulated at the invasive edges of pancreatic tumors and expressed VEGF and bFGF, in regions of high MVD within the tumors. There were significant positive correlations between MC density and MVD; moreover, increased numbers of MCs directly correlated with lymph node metastasis. Although survival was lower in patients with high MC density, the difference did not reach significance [12] . Likewise, high MC density in the invasive margins of pancreatic tumors was correlated with increased vascularization and tumor invasion and increased lymph node metastases; moreover, high MC numbers were independent prognostic indicators for reduced overall survival [13] . Similarly, patients with high MC density in the stroma of pancreatic tumors had significantly worse median disease-free survival times compared with patients with low MC density [14] . In the latter study, in vitro evidence indicated cross-talk between MCs and tumors; pancreatic tumor cells recruited MCs, and MCs promoted growth and invasion of pancreatic tumors [14] .
The presence of tumor-associated MCs is correlated with favorable prognosis in some human cancers
In some human cancers, high MC density in tumors is associated with favorable prognosis. A study of over 4,000 breast cancer patients reported that the mean survival time of patients with any stromal MCs was significantly better compared with those lacking stromal MCs: 15 years with MCs compared to 13.9 years without MCs [15] . The presence of MCs also correlated with favorable prognosis in high hormone-responsive breast cancers [16] . Histological images of MCs degranulating near dying tumor cells suggested a cytotoxic effect of MCs on breast cancers. In breast cancers, MCs were suggested as a source of IL-4, which arrests the growth and induces apoptosis of breast cancer cells in vitro [17] .
A few studies have reported that the microanatomical location of MCs within the TME was prognostic. In prostate cancer, a high density of MCs within the tumor mass (intratumoral) was associated with favorable prognosis. In contrast, a high density of MCs surrounding (peritumoral) prostate tumors was significantly associated with unfavorable prognosis and poor survival [18] . The peritumoral MCs in human prostate cancer expressed pro-angiogenic bFGF, suggesting that they enhanced tumor angiogenesis [18] . The microanatomical location of MCs was also important in lung cancer. In a study of non-small cell lung cancer patients, the presence of MCs within tumor islets, but not stroma, was a favorable prognostic indicator [19] .
The studies above suggest that high MC density can be correlated with either favorable or unfavorable prognostic significance in human cancers depending on the type of cancer, perhaps the methods used to assess MC presence and density, as well as where MCs are located in the TME. For understanding the mechanisms of MC functions in cancer, experimental models of cancer may be valuable and will be discussed next.
Mechanisms of MC-mediated tumor promotion from murine models
The MC growth factor, stem cell factor (SCF), has been implicated in one study in both recruiting and activating tumor-associated MCs and promoting inflammation in the TME [20] . SCF was shown to be produced by many mouse and human tumor cell lines as well as by primary mouse and human tumors. Furthermore, tumors that were engineered to knock down gene expression of SCF were unable to attract MCs to the TME and grew more slowly than normal. Injection of large numbers of bone marrowderived MCs into tumor-bearing mice resulted in immune suppression (reduced T cell proliferation and NK cellderived IFN-c), increased inflammation (expression of IL-6, TNF-a, and VEGF), and increased expression of immune-suppressive TGF-b and IL-10 in the TME. All of these MC-induced alterations of the TME were shown to require SCF. However, since large numbers of exogenous MCs were injected into tumor-bearing mice, the physiological relevance of the latter experiments is unclear.
Mice [21, 22] . These strains of mice with MC deficiencies have been used in tumor models to define roles for MCs in cancer.
A number of strains of mice have been genetically modified to develop inducible tumors that progress in predictable stages from preneoplasia to malignancy. An advantage of inducible tumors is that the tumor microenvironment can be studied from the earliest stages. Inducible tumor models facilitate identifying leukocyte subsets and their temporal sequence of appearance. Furthermore, inducible mouse tumors offer the opportunity to target cells and molecules during tumor progression in order to understand cause and effect. Insights into the roles of MCs in mouse models of inducible tumors are discussed below.
A transgenic (Tg) mouse model of squamous cell carcinoma was generated by expressing the human papilloma virus gene 16 in basal keratinocytes (K14-HPV-16 Tg mice). Such mice develop epidermal hyperplasia that progresses to squamous cell carcinoma [23] . MCs infiltrated premalignant epidermal lesions at a time coinciding with the angiogenic switch. Moreover, MCs accumulated at the invasive front of tumor-stroma borders, but not within the core of tumors. MC tryptase stimulated proliferation of dermal fibroblasts and MC-chymase-promoted remodeling of the extracellular matrix. Both proteases released proangiogenic molecules from the extracellular matrix. Thus, MCs promoted squamous cell carcinoma in this model by stimulating premalignant angiogenesis, tumor cell proliferation, and by MC proteases remodeling the stromal architecture at the invasive front of tumors [23] .
A mouse model of pancreatic islet cell cancer was generated by expressing an inducible c-Myc oncogene together with the anti-apoptosis protein Bcl-XL in insulinproducing islet cells (myc ? bcl ? Tg mice) [24] . Activation of c-Myc in these mice caused rapid proliferation of islet cells and expansion of pancreatic islet tumors. Further investigation showed that within 2 h of c-Myc activation, there was elevated expression of MC-recruiting chemokines within the islets. Within 24 h of c-Myc activation, the invasive margins of the tumors became infiltrated by MCs, which coincided with the onset of tumor angiogenesis. As MCs were the only immune cells present, they were implicated in promoting angiogenesis of pancreatic islet tumors. To further investigate the role of MCs in pancreatic tumors, myc ? bcl ? Tg mice were bred onto the W sh MCdeficient strain. The absence of MCs in W sh myc ? bcl ? Tg mice completely abolished the expansion of pancreatic tumors; that is, in MC-deficient mice, c-Myc-activated cells divided rapidly and then became hypoxic and died rather than forming tumors. This indicates that MCs are required for c-Myc-driven pancreatic tumor expansion. Similarly, blocking MC degranulation (i.e., release of stored bioactive mediators from MC granules) with cromolyn also abolished c-Myc-driven tumor expansion in myc ? bcl ? Tg mice. In addition, MCs were required for the survival of previously established pancreatic tumors; mice with established tumors were treated with cromolyn, which induced hypoxia, tumor cell apoptosis, and a dramatic regression of the tumors. Thus, in the myc ? bcl ? model of pancreatic cancer, MCs were not only essential for angiogenesis, growth, and expansion of nascent pancreatic tumors, but also required to sustain established pancreatic tumors [24] .
The roles of MCs were also investigated in several mouse models of colorectal cancer [25] . Mice with inducible overexpression of b-catenin in intestinal cells develop adenomatous polyps, which were densely infiltrated with MCs from the earliest time points. Similarly, two other strains of mice that develop intestinal polyps (APC D468 and Rag -/-Min) also had a striking accumulation of MCs in polyps [25] . Preventing MC migration in the APC D468 strain reduced the vascularization, size, and numbers of intestinal polyps. Also, treatment of the APC D468 strain with cromolyn reduced the size, numbers, and vascularization of intestinal polyps. Therefore, similar to the role of MCs in pancreatic cancer, MCs are required for the development of polyps and colorectal cancer by promoting tumor angiogenesis and expansion of tumors [25] . In summary, a wealth of evidence from human cancers and mouse models of cancer indicates that MCs contribute to tumor invasion and angiogenesis, both vital for the macroscopic expansion of tumors.
In addition to MCs promoting angiogenesis and expansion of tumors, we propose an immunosuppressive role for MCs in the TME that is analogous to their role of promoting suppression by Foxp3
? regulatory T (T reg ) cells in the immune-suppressive microenvironment of a tolerated allogeneic skin graft [4] . Within the tolerant skin allograft, one sees the infiltration of alloreactive T eff and T reg , in a dynamic equilibrium that favors immune suppression by the T reg [4, 26] . We propose that MCs suppress the development of protective antitumor immune responses, in part, by promoting Treg suppression in the TME. Also, our studies in allograft tolerance show that MCs ''condition'' dendritic cells (DCs) (in part by producing GM-CSF and TNF-a) to mediate tolerance by controlling DC migration, longevity, and ability to present antigen in an immunogenic fashion [27] .
Potential mechanisms of antitumor activities of MCs in murine models
Although MCs surround many tumors at a high density and support tumor growth, there is some evidence that the protumoral activities of MCs may be subverted by targeting these cells to promote tumor destruction. In one example, TLR2 (Toll receptor) agonist activation of MCs was also used to stimulate MC-mediated antitumor activity in a mouse model of B16 melanoma [28] . Alternatively, triggering MC degranulation can subvert their suppression. As noted above, MCs are in a delicate equilibrium with T reg cells, maintaining immune suppression in established tolerated allografts [4, 26] . MCs can be degranulated by IgE antibody binding and cross-linking their cell surface FceR1. Degranulating MCs by IgE antibody in mice with established tolerated allografts resulted in T reg impairment and acute CD4 and CD8 T-cell-mediated tissue destruction [26] . Such acute T-cell-mediated destruction is an important goal of immune therapy for cancer. One promising approach to elicit MC targeting of tumors is to use therapeutic antitumor antibodies of the IgE class. IgE-directed responses against tumors have proven to promote tumor destruction; reviewed in Ref. [29] . IgE antibodies were bound to tumors using biotinylated antitumor IgG bridged to biotinylated IgE with avidin; this resulted in slower growth of IgE-loaded tumors [30] . An anti-ovarian tumor antibody of the IgG class was engineered to express the IgE Fc domain. The IgE antibodies were more effective than the IgG antibodies of identical specificity in promoting tumor cytotoxicity [31] . Mice also have been vaccinated with oral mimitopes (peptides mimicking antibody binding sites on tumors) to generate antitumor IgE antibodies [32] [33] [34] 
Intratumoral T cells in human cancers and their prognostic significance
T cells producing IFN-c and cytotoxic molecules are important antitumor effector cells. In a number of studies of humans with ovarian cancer, melanoma, colorectal, pancreatic, and lung cancers, a favorable prognosis is associated with the presence of large numbers of intratumoral T cells, particularly CTL and Th1 cells [35] [36] [37] [38] [39] [40] [41] [42] . Long-term survival in colorectal cancer is significantly associated with the presence of high densities of intratumoral CD3
? CD8 ? CD45RO ? memory T cells [38] . Moreover, gene expression profiling has identified a coordinately expressed cluster of genes associated with adaptive Th1 immunity; high expression of this cluster was associated with favorable prognosis in colorectal cancer [38] . Further analysis revealed that coordinated high expression of both the CTL-associated gene, granulysin (GNLY) in combination with high expression of the Th1-associated gene, interferon-regulatory factor-1 (IRF-1) is significantly associated with long-term disease-free survival from colorectal cancer (over a decade) [35] . In contrast, patients with high expression of VEGF genes within their tumors had unfavorable prognoses and reduced survival, even if they had other favorable T cell and gene expression profiles [35] . The detailed analyses of human cancers discussed above have provided important clues on the characteristics of protective and detrimental immune responses to tumors. These clues can be used to develop more effective immune therapies for cancer. However, the cells and molecules that control the balance between protective and non-protective immune responses are still poorly defined. In particular, how MCs influence T cell responses to cancer has not been well studied. For such studies, mouse models of cancer have provided insights. T cells accumulating within tumors are associated with favorable prognosis. Therefore, it is important to understand how MCs impair these important aspects of antitumor immune responses.
We hypothesize that MCs impair T cell accumulation within tumors indirectly by promoting angiogenesis. Increasing evidence suggests that molecules promoting tumor angiogenesis also impair the accumulation of intratumoral T cells, recently reviewed [43, 44] . For T cells to enter the TME, they must cross the endothelial cell barrier by diapedesis [45] . An initial step in diapedesis is the adhesion of T cells by their integrins, LFA-1 and VLA-1, to the endothelial cell adhesion molecules, ICAM and VCAM, respectively. Angiogenesis in tumors has been shown to reduce ICAM and VCAM expression on endothelial cells. In vitro cultured endothelial cells showed significantly reduced expression of both ICAM and VCAM in the presence of either VEGF or bFGF [46] . Also, in vivo blockade of angiogenesis restored leukocyte adhesion to vessel walls and significantly increased leukocyte infiltration into tumors [47] . Furthermore, intravital microscopy showed that tumor-bearing mice had reduced interactions of leukocytes with blood vessels [46] . Finally, VEGF blockade, not alone, but in combination with antitumor vaccines or adoptive T cell therapy, increased the infiltration and accumulation of intratumoral T cells [48] [49] [50] . These studies have prompted the interesting suggestion that blockade of tumor angiogenesis renders tumors more accessible to the immune system [43] . We hypothesize that interfering with or deleting MCs will synergize with antitumor vaccines to promote effective killing of tumor cells.
How MCs impair the generation of antitumor IFN-c ? T cells is under investigation now. MCs produce a plethora of molecules capable of influencing immune responses [51] . MCs are known to produce molecules that can impair dendritic cell-mediated generation of CTL and Th1 cells by suppressing IL-12 production by DCs. These molecules include VEGF, IL-10, histamine and prostaglandins and possibly others yet to be identified [52] [53] [54] [55] [56] . MC expression of VEGF in the TME has been well documented [12, 57, 58] . Moreover, VEGF was the first tumor-derived factor reported to inhibit DC differentiation [59] , and its critical role in mediating tumor-induced defects in DC differentiation has been proven both in vitro and in vivo [60] . Furthermore, administration of neutralizing VEGF antibody to tumor-bearing animals resulted in improved DC differentiation [61] . Our preliminary studies indicate that blocking VEGFR2 also enhanced the resistance of wild-type female, but not male, mice to MB49 tumors, suggesting a potential role for VEGF impairing tumor immunity in this model. Also, our recent work showed that MC-derived TNF-a and GM-CSF conditioned graft-derived dendritic cells that mediate allograft tolerance [27] . Such tolerogenic dendritic cells accumulated in draining lymph nodes where they dominantly suppressed T cell responses. The role of MCs in promoting tolerogenic DCs in the TME is currently under investigation.
We have observed a novel role of MCs in regulation of antitumor immunity by their expression of tryptophan hydroxylase-1 (Tph-1), an enzyme using tryptophan as a substrate to produce serotonin. Tph-1 is therefore capable of depleting local tryptophan, which may have detrimental effects on antitumor T cells. Mice (females but not males) with a genetic deficiency of Tph-1 were better able to control MB49 tumors, and this was T-cell-mediated; Tph-1-deficient mice lost their superior tumor resistance when CD4 and CD8 T cells were depleted. Moreover, Tph-1-deficient mice had significantly increased IL-17 and IFN-c ELISPOT responses to tumor antigens. Also, W sh female mice lost their superior resistance to MB49 tumors when reconstituted with WT, but not Tph-1-deficient mast cells; this implicates MCs as an essential source of Tph-1 in suppressing tumor resistance. Taken together, MCs inhibit antitumor T cell immunity, at least in part, by their expression of Tph-1 (E. Nowak et al., manuscript in preparation).
MCs may also influence T cell responses by forming immunological synapses with and presenting antigens to T cells [62] . MCs can be induced to express MHC II both in vitro and in vivo. In co-cultures MCs, presented MHC class II-associated antigens to CD4
? T cells, and there was a preferential expansion of T reg cells in these in vitro cultures [63] . However, the in vivo occurrence and significance of MCs presenting antigens to T reg cells has yet to be demonstrated. MCs and T reg have regulatory effects on each other. MCs are capable of producing TGF-b [64] which enhances Treg differentiation [65] . T reg recruit MCs to tolerant allografts, and both subsets are essential for maintaining skin graft tolerance [4] . Conversely, in tolerant allografts, degranulation of MCs induced rapid allograft rejection and loss of T reg -suppressive functions [26] . Moreover, in colorectal cancer, MCs promote T reg production of pro-inflammatory cytokines, such as IL-6, that promote tumor progression [66] . The reciprocal interactions of MCs and T reg in cancer are well summarized in a recent review [67] ? -MCs [69] . Another model of MC-specific gene expression contains a promoter that is restricted to chymase-expressing MCs, located in mucosal tissues [70] .
Concluding remarks
The roles of MCs in cancer are far from being understood and many questions remain. Current evidence favors the idea that MCs influence tumor angiogenesis, tumor invasion, immune suppression, and contribute to the composition of the immune-suppressive TME. Although MCs have been demonstrated to secrete molecules with angiogenic and immune-suppressive functions, the extent to which MCs are a relevant source of these immune-suppressive molecules in the TME is an unresolved, but important, question. As mentioned above, new transgenic mouse strains allowing the precise deletion of genes within MCs will help elucidate the roles of MCs and MC-derived molecules within the TME. Important future directions will be to identify molecules that provide signals to MCs during initiation of tumors, to identify the molecules MCs produce in response to the signals, and to understand how MCderived molecules influence the outcome of antitumor immune responses. MCs have a great deal of flexibility during initiation of immune responses and are capable of enhancing or suppressing adaptive immunity. Preclinical studies suggest that blocking MC functions, degranulating MCs, or depleting MCs in some types of cancer might be an effective therapeutic strategy. However, a better understanding of how MCs influence antitumor responses might also suggest new strategies to therapeutically target MCs in the TME to improve protective immune responses. It is important to note that the extent to which MCs are a major biological source of immune-suppressive molecules in the TME and lymph nodes has yet to be established; therefore, this is presented as a hypothetical model. VEGF vascular endothelial growth factor; GM-CSF granulocyte macrophage colony stimulating factor; T 
